Latest Share Purchase Plans News

Aeris Resources has launched a Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy shares at a discounted price, aiming to raise up to $10 million for working capital.

Mount Hope Mining has issued over six million shares via placement and is set to offer additional shares through a share purchase plan, signaling a strategic capital raise.

Arafura Rare Earths secures an ASX waiver allowing eligible shareholders to vote on its upcoming Share Purchase Plan, ensuring broader participation in a key capital raising step.

Kingsland Minerals has successfully closed an oversubscribed Share Purchase Plan, raising A$543,000 to advance its Leliyn Graphite Project and exploration efforts.

Barton Gold Holdings reminds eligible shareholders that its Share Purchase Plan (SPP) closes on 6 November 2025, offering shares at $1.25 each, the same price as a recent institutional placement. The SPP provides a cost-free opportunity for Australian and New Zealand investors to increase their stake ahead of the company’s next growth phase.

Whitefield Income Limited has launched a $40 million Share Purchase Plan offering eligible shareholders a discounted entry point to increase their holdings ahead of the December dividend.

PARKD Limited has raised $1 million to fund its East Coast expansion, secured a new prefabrication facility in NSW, and landed its first pilot project with McNab Group, marking a pivotal step in its national rollout.

Nimy Resources has completed a major drilling campaign confirming high-grade gallium mineralisation and made significant copper-nickel discoveries at its Mons Project in Western Australia, while forging strategic ties with US partners to advance its critical minerals ambitions.

Theta Gold Mines has commenced bulk earthworks at its flagship TGME gold project in South Africa and secured nearly US$40 million in combined equity and debt funding, marking a pivotal step toward production.

Santana Minerals reports robust progress on its Bendigo-Ophir Gold Project with an updated Pre-Feasibility Study, strategic land acquisitions, and a substantial capital raise, positioning the project for development in 2026.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.